In order to investigate the mechanisms of action involved in the effects of EVs of SSc patients in HUVECs, we conducted experiments in the presence and absence of inhibitors of the PI3K/Akt, AMPK, MEK1/2/ERK1/2, PKA, and CAMKII pathways, namely wortmannin, dorsomorphine, UO126, H89, and KN93, respectively. The gene discussed is MAP2K1; the disease is systemic sclerosis.